The effects of sunitinib on endometriosis

Simple item page
dc.contributor.authorPala H.G.
dc.contributor.authorErbas O.
dc.contributor.authorPala E.E.
dc.contributor.authorUlkumen B.A.
dc.contributor.authorAkman L.
dc.contributor.authorAkman T.
dc.contributor.authorOltulu F.
dc.contributor.authorYavasoglu A.
dc.date.accessioned2024-07-22T08:13:46Z
dc.date.available2024-07-22T08:13:46Z
dc.date.issued2015
dc.description.abstractThe aim of the present study was to evaluate the effect of sunitinib on endometriotic implants and adhesions in a rat endometriosis model. An experimental endometriosis model was created in 21 rats. These rats were randomly divided into three groups: Group 1 (control group, 7 rats) was given no medication; Group 2 (sunitinib group, 7 rats) was given 3 mg/ kg per day of oral sunitinib; and Group 3 (danazol group, 7 rats) was given 7.2 mg/kg per day of oral danazol. The volume of endometriotic implants was calculated. The extent and severity of adhesions were evaluated. The groups were compared by the Student's t-test, analysis of variance (ANOVA) and the Mann-Whitney U test. There was no statistically significant difference in the mean volume of endometriotic implants before medication between three groups. The volume of implants and extent, severity, total score of adhesions were significantly decreased after medication in Group 2 and Group 3. We noted that the volume of the endometriotic implants and adhesion formation were decreased both after sunitinib and danazol treatment. As a result, sunitinib seems to be effective for endometriotic peritoneal lesions. The effects of sunitinib in rat models give hope for improving the treatment of human endometriosis and prevention of pain symptoms. © 2014 Informa UK, Ltd.
dc.identifier.DOI-ID10.3109/01443615.2014.941345
dc.identifier.issn01443615
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/16408
dc.language.isoEnglish
dc.publisherInforma Healthcare
dc.subjectAngiogenesis Inhibitors
dc.subjectAnimals
dc.subjectDanazol
dc.subjectDisease Models, Animal
dc.subjectEndometriosis
dc.subjectEstrogen Antagonists
dc.subjectFemale
dc.subjectIndoles
dc.subjectPeritoneal Diseases
dc.subjectPyrroles
dc.subjectRandom Allocation
dc.subjectRats
dc.subjectRats, Sprague-Dawley
dc.subjectTissue Adhesions
dc.subjectdanazol
dc.subjectsunitinib
dc.subjectangiogenesis inhibitor
dc.subjectantiestrogen
dc.subjectdanazol
dc.subjectindole derivative
dc.subjectpyrrole derivative
dc.subjectsunitinib
dc.subjectanimal experiment
dc.subjectanimal model
dc.subjectanimal tissue
dc.subjectArticle
dc.subjectcontrolled study
dc.subjectdrug efficacy
dc.subjectendometriosis
dc.subjectfemale
dc.subjecthistopathology
dc.subjectimplant
dc.subjectlaparotomy
dc.subjectnonhuman
dc.subjectpain
dc.subjectpriority journal
dc.subjectrat
dc.subjectanimal
dc.subjectcomplication
dc.subjectdisease model
dc.subjectendometriosis
dc.subjectPeritoneal Diseases
dc.subjectrandomization
dc.subjectSprague Dawley rat
dc.subjectTissue Adhesions
dc.titleThe effects of sunitinib on endometriosis
dc.typeArticle

Files

Collections

Scopus Koleksiyonu